Bijoy Hans Ltd is in the business of Pharmaceutical, Medical and Cosmetics goodsBusiness Overview: Company does Wholesale of Pharmaceutical and Medical Goods and Cosmetics. It offers various pharmaceutical formulations such as tablets, capsules, syrups, suspension and powders, focusing on segments viz. Antibiotics, Cough/cold/allergy, H-1 receptor Antagonist (Antiulcerant), Nutraceutical, and NSAIDS
Bijoy Hans Limited is changing its name to Arvaya Healthcare Limited. This corporate rebranding, along with a new Scrip ID ARVAYA, will become effective from July 13. This move signals a clearer strategic focus on the healthcare sector, aligning the company's identity with its business direction. Shareholders should note this...
Arvaya Healthcare Limited has submitted a compliance certificate confirming the efficient processing of dematerialisation requests for its equity shares. The company's Registrar and Transfer Agent verified that all physical share certificates submitted for conversion to electronic form were duly processed and cancelled, with investor names correctly updated in depository records....
Arvaya Healthcare has announced a board meeting on July 11, 2026. Key agenda items include acquiring Sushodha Institute, considering a preferential share issue (share swap), and a potential rights issue to raise capital.
Arvaya Healthcare has announced a board meeting on July 04, 2026, to consider appointing Mr. Bidari Kotresh Anilkumar as Executive Director and approving Q1 financial results. Trading window closed from July 1 until results.
Arvaya Healthcare has received approval from BSE to reclassify four individuals from its promoter group to the public category. Notably, these reclassified members held no shares in the company, meaning their reclassification does not alter the current ownership structure. Post-reclassification, the promoter group's shareholding remains at 30.62%, while public shareholders...
